GlassScriptPhysician profile
Cicely Moreno
NPI 1285171827
$1,006.97
in general payments reported to CMS, 2019-2025
18 companies · $420 in 2025
The $420 reported for 2025 was more than what 76% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.46 · 2022: $246 · 2023: $270 · 2024: $31.77 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $197.19 | 2025 | Brixadi |
| Abbvie INC. | $193.66 | 2022-2025 | |
| Indivior INC. | $73.23 | 2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.64 | 2025 | Caplyta |
| Lilly USA, LLC | $59.85 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $56.83 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $53.57 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $42.00 | 2022-2023 | Gardasil 9, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $38.99 | 2021-2023 | Farxiga |
| Amgen INC. | $37.39 | 2022 | |
| Astellas Pharma US INC | $34.38 | 2022-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $33.97 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.71 | 2022 | |
| Novo Nordisk INC | $27.33 | 2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $21.73 | 2023 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.72 | 2025 | Accolade Sr |
| Collegium Pharmaceutical, INC. | $16.50 | 2025 | Belbuca |
| E.R. Squibb & Sons, L.L.C. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cicely Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.